Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

O'Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, Ochs M, Hawkins S, Hutchinson M, O'Rourke K, Vandenbroeck K.

Pharmacogenomics. 2009 Jul;10(7):1177-86. doi: 10.2217/pgs.09.41.

2.

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.

Kulakova OG, Tsareva EY, Boyko AN, Shchur SG, Gusev EI, Lvovs D, Favorov AV, Vandenbroeck K, Favorova OO.

Pharmacogenomics. 2012 Nov;13(15):1689-700. doi: 10.2217/pgs.12.161.

PMID:
23171334
3.

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO.

Pharmacogenomics. 2014 Apr;15(5):679-85. doi: 10.2217/pgs.14.26.

PMID:
24798724
4.

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR.

Arch Neurol. 2008 Mar;65(3):337-44. doi: 10.1001/archneurol.2008.47. Epub 2008 Jan 14.

PMID:
18195134
5.

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.

Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, Gusev EI, Vandenbroeck K, Favorova OO.

Pharmacogenomics. 2012 Jan;13(1):43-53. doi: 10.2217/pgs.11.136. Epub 2011 Nov 23.

PMID:
22111603
6.

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B.

Pharmacogenomics J. 2012 Jun;12(3):238-45. doi: 10.1038/tpj.2011.14. Epub 2011 Apr 19.

PMID:
21502966
7.

Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.

Vandenbroeck K, Matute C.

Pharmacogenomics. 2008 May;9(5):639-45. doi: 10.2217/14622416.9.5.639. Review.

PMID:
18466107
8.

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.

Vandenbroeck K, Comabella M.

J Interferon Cytokine Res. 2010 Oct;30(10):727-32. doi: 10.1089/jir.2010.0085. Review.

PMID:
20836710
9.

Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.

Guerrero AL, Tejero MA, Gutiérrez F, Martín-Polo J, Iglesias F, Laherran E, Martín-Serradilla JI, Merino S.

Neurologia. 2011 Apr;26(3):137-42. doi: 10.1016/j.nrl.2010.06.003. Epub 2010 Nov 5. English, Spanish.

10.

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.

Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, Patterson C, McDonnell G, Hawkins S, Vandenbroeck K.

Clin Pharmacol Ther. 2005 Dec;78(6):635-46.

PMID:
16338279
11.

CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.

Alvarez-Lafuente R, Blanco-Kelly F, Garcia-Montojo M, Martínez A, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Garcia-Martinez A, De la Concha EG, Urcelay E, Arroyo R.

Mult Scler. 2011 May;17(5):513-20. doi: 10.1177/1352458510393263. Epub 2010 Dec 21.

PMID:
21177319
12.

An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients.

Martínez A, de las Heras V, Mas Fontao A, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R.

J Neuroimmunol. 2006 Apr;173(1-2):196-9. Epub 2006 Jan 20.

PMID:
16430971
13.

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

Tsareva EIu, Kulakova OG, Makarycheva OIu, Boĭko AN, Shchur SG, Lashch NIu, Popova NF, Gusev EI, Bashinskaia VV, L'vov DV, Favorov AV, Ochs MF, Favorova OO.

Mol Biol (Mosk). 2011 Nov-Dec;45(6):963-72. Russian.

PMID:
22295566
14.

Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.

Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A.

Clin Immunol. 2008 Sep;128(3):306-13. doi: 10.1016/j.clim.2008.04.007. Epub 2008 Jun 9.

PMID:
18539537
15.

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X.

Arch Neurol. 2009 Aug;66(8):972-8. doi: 10.1001/archneurol.2009.150.

PMID:
19667218
16.

HLA class II and response to interferon-beta in multiple sclerosis.

Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo JA, Alonso A, Romero F, Leyva L, Alonso A, Luque G, de Ramón E.

Acta Neurol Scand. 2005 Dec;112(6):391-4.

PMID:
16281922
17.

Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta.

Gilli F.

J Interferon Cytokine Res. 2010 Oct;30(10):733-41. doi: 10.1089/jir.2010.0098. Review.

PMID:
20874250
18.

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, Lechner-Scott J, Kermode AG, Slee M, Taylor BV, Vandenbroeck K, Comabella M, Boneschi FM; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), King C.

Pharmacogenomics J. 2017 Jul;17(4):312-318. doi: 10.1038/tpj.2016.20. Epub 2016 Mar 22.

PMID:
27001119
19.

Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A.

PLoS One. 2014 Jul 15;9(7):e102331. doi: 10.1371/journal.pone.0102331. eCollection 2014.

20.

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundström E, Ehrlich S, Wernecke KD, Volk HD, Zipp F.

Lancet. 2003 Jun 14;361(9374):2036-43.

PMID:
12814715

Supplemental Content

Support Center